^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    c-MET inhibitor

    Related drugs:
    6d
    Amivantamab With Tyrosine Kinase Inhibitors (TKI) for Advanced NSCLC With ALK, ROS1, or RET Alterations (clinicaltrials.gov)
    P1/2, N=12, Active, not recruiting, University of Colorado, Denver | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    ALK (Anaplastic lymphoma kinase) • RET (Ret Proto-Oncogene) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    RET fusion • ALK fusion • ROS1 fusion
    |
    VENTANA ALK (D5F3) CDx Assay
    |
    Rybrevant (amivantamab-vmjw)
    7d
    Osimertinib with or without savolitinib as first-line treatment for MET-aberrant, EGFR-mutant NSCLC: randomized phase 2 trial (FLOWERS). (PubMed, Nat Commun)
    Treatment-related adverse events of grade 3 or higher occurred in 2 patients (8.7%) in cohort 1 and 12 patients (57.1%) in cohort 2. Osimertinib plus savolitinib showed promising antitumor activity and manageable safety.
    P2 data • Journal
    |
    EGFR (Epidermal growth factor receptor) • MET (MET proto-oncogene, receptor tyrosine kinase)
    |
    EGFR mutation • MET amplification • MET overexpression • MET mutation
    |
    Tagrisso (osimertinib) • Orpathys (savolitinib) • simmitinib (SYHA1817)
    12d
    Zanzalintinib in Combination With Ipilimumab and Nivolumab in Patients With Metastatic Soft Tissue Sarcoma (clinicaltrials.gov)
    P1, N=18, Recruiting, Washington University School of Medicine | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • zanzalintinib (XL092)
    12d
    Osimertinib Combined With Savolitinib in the Treatment of NSCLC With Low Copy Number MET Amplification (clinicaltrials.gov)
    P2, N=60, Recruiting, Qingdao Central Hospital
    New P2 trial
    |
    MET (MET proto-oncogene, receptor tyrosine kinase)
    |
    MET amplification
    |
    Tagrisso (osimertinib) • Orpathys (savolitinib) • simmitinib (SYHA1817)
    14d
    MDX-2001-101 study protocol: a phase I/IIa, multicenter, first-in-human, open-label clinical trial evaluating MDX2001 monotherapy in patients with advanced solid tumors. (PubMed, Future Oncol)
    Here, we present the protocol design for study MDX-2001-101, a multicenter, open-label, phase I/IIa clinical trial designed to evaluate the safety, tolerability, and antitumor effects of MDX2001 in patients with advanced solid tumors. The study comprises a phase Ia dose escalation guided by a Bayesian optimal interval design with a targeted maximum tolerated dose toxicity rate of 30%, a phase Ib dose expansion, and a phase IIa indication expansion.
    P1/2 data • Journal • First-in-human
    |
    MET (MET proto-oncogene, receptor tyrosine kinase)
    17d
    Phase II Study of EMB-01 in Recurrent/Metastatic Colorectal Cancer Patients (clinicaltrials.gov)
    P2, N=54, Recruiting, EpimAb Biotherapeutics (Suzhou)Co., Ltd.
    New P2 trial
    |
    BRAF (B-raf proto-oncogene)
    |
    bafisontamab (EMB-01)
    25d
    Harnessing Insights of Hepatocyte Growth Factor Kringle 3 Domain to Develop c-Met Targeted Positron Emission Tomography Probe. (PubMed, J Med Chem)
    In conclusion, the strategy of using the interface residues has been successfully explored for the discovery of new c-Met binders. [68Ga]Ga-SMIC-1014 shows a high tumor imaging performance and potential as a c-Met-targeted diagnostic probe.
    Journal
    |
    MET (MET proto-oncogene, receptor tyrosine kinase) • HGF (Hepatocyte growth factor)
    |
    MET overexpression
    |
    onartuzumab (RG3638)
    26d
    CHRYSALIS-2: A Study of Lazertinib as Monotherapy or in Combination With Amivantamab in Participants With Advanced Non-small Cell Lung Cancer (clinicaltrials.gov)
    P1, N=701, Active, not recruiting, Janssen Research & Development, LLC | Trial completion date: Jun 2026 --> Mar 2028
    Trial completion date
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR exon 20 insertion • EGFR expression • EGFR exon 20 mutation
    |
    Tagrisso (osimertinib) • carboplatin • pemetrexed • Rybrevant (amivantamab-vmjw) • Lazcluze (lazertinib)
    28d
    Tepotinib Phase II in NSCLC Harboring MET Alterations (VISION) (clinicaltrials.gov)
    P2, N=337, Active, not recruiting, EMD Serono Research & Development Institute, Inc. | Trial completion date: Oct 2025 --> Apr 2026
    Trial completion date
    |
    MET (MET proto-oncogene, receptor tyrosine kinase)
    |
    Tepmetko (tepotinib)
    28d
    ASKC202-001: Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumor Activity of ASKC202 With or Without ASK120067 (clinicaltrials.gov)
    P1, N=150, Recruiting, Jiangsu Aosaikang Pharmaceutical Co., Ltd. | Trial completion date: May 2025 --> Dec 2027 | Trial primary completion date: May 2024 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    MET (MET proto-oncogene, receptor tyrosine kinase)
    |
    MET amplification
    |
    limertinib (ASK120067) • ASKC202
    28d
    Cancer-associated fibroblasts confer ALK inhibitor resistance in EML4-ALK-driven lung cancer by concurrent integrin and MET signaling. (PubMed, Sci Signal)
    Moreover, the combination of the ALK inhibitor alectinib with the MET inhibitor capmatinib and/or the integrin inhibitor cilengitide was more effective than single-agent treatment in suppressing tumor growth in allografted mice. The findings illustrate a previously unappreciated complex nature of concurrent paracrine and juxtacrine mechanisms of CAF-driven resistance that may inform the development of more effective therapeutic approaches.
    Journal
    |
    EML4 (EMAP Like 4)
    |
    ALK fusion
    |
    Alecensa (alectinib) • Tabrecta (capmatinib) • Cilcane (cilengitide)